Dopamine News and Research

RSS
Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.
Methamphetamine users more likely to develop Parkinson's disease

Methamphetamine users more likely to develop Parkinson's disease

Essential criteria for clinical diagnosis of restless legs syndrome

Essential criteria for clinical diagnosis of restless legs syndrome

Scientists discover new dominant gene linked to Parkinson's

Scientists discover new dominant gene linked to Parkinson's

Lack of kidney dopamine leads to high blood pressure and shorter life span

Lack of kidney dopamine leads to high blood pressure and shorter life span

Gut hormone changes the ability of food-related cues to alter dopamine levels

Gut hormone changes the ability of food-related cues to alter dopamine levels

Eating disorder behavior may directly affect brain function

Eating disorder behavior may directly affect brain function

PDF announces $1M for 11 novel Parkinson's research projects

PDF announces $1M for 11 novel Parkinson's research projects

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers to use tiny worms for Parkinson's project

ACS to honor Brookhaven Lab's senior chemist for brain research

ACS to honor Brookhaven Lab's senior chemist for brain research

Cocaine contaminated with livestock de-worming drug causes painful purpura

Cocaine contaminated with livestock de-worming drug causes painful purpura

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

Music and drama therapy improve physical, emotional components of Parkinson's

Music and drama therapy improve physical, emotional components of Parkinson's

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.